GLP-1 receptor agonists show little effect on obesity-related cancer risk
1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant ...
Tag: Kidney Cancer
Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1
Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally advanced or metastatic clear cell ...
Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma
1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events ...
Atezolizumab added to cabozantinib does not improve clinical outcomes in patients with metastatic renal cell carcinoma
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...
Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there ...
Patient Basics: Kidney Cancer
Originally published by Harvard Health. What Is It? The kidneys are a pair of bean-shaped, fist-sized organs below the rib cage ...
